⚠️
Important: VAERS reports alone cannot determine if a vaccine caused an adverse event. Reports may contain incomplete, inaccurate, or unverified information. Correlation does not equal causation.
Urinary tract infection
4,442 total reports56.3% serious outcomes
Share
4,442
Total Reports
412
Deaths
2,089
Hospitalizations
56.3
Severity Rate
% serious outcomes
About Urinary tract infection Reports
Urinary tract infection has been reported 4,442 times in VAERS from 1990 to 2026.
Of these reports, 412 were associated with death (9.28%) and 2,089 involved hospitalization.
The overall serious outcome rate (death or hospitalization) for reports mentioning Urinary tract infection is 56.3%.
Understanding Urinary tract infection in VAERS
•Temporal association only: These reports show Urinary tract infection occurred after vaccination, not necessarily because of vaccination.
•Background rates matter: Many symptoms occur naturally at baseline rates in the population, unrelated to vaccination.
•Reporting variability: Medical terminology may be used differently by various healthcare providers and over time.
•Investigation needed: High-frequency reports may trigger further epidemiological studies to determine causation.
What This Data Shows
Most Associated Vaccines: The vaccines most frequently mentioned in reports with Urinary tract infection. This may reflect usage patterns, not causation.
Severity Patterns: The percentage of reports that involve serious outcomes can help prioritize safety investigations.
Reporting Trends: Changes in reporting frequency over time may reflect increased awareness, media attention, or actual safety signals.
Most Associated Vaccines
1. COVID193,935
2. HPV4271
3. HIBV230
4. FLU3203
5. HEP181
6. COVID19-2181
7. VARZOS139
8. DTAP138
9. OPV129
10. IPV104
Quick Facts
Reports:4,442
Deaths:412
Hospitalizations:2,089
Mortality Rate:9.28%
Severity Rate:56.3%
Related Analysis
Explore Further
Data Source
This data comes from the Vaccine Adverse Event Reporting System (VAERS), jointly managed by CDC and FDA.